Navigation Links
New agent strikes at respiratory syncytial virus replication
Date:5/5/2008

GALVESTON, Texas University of Texas Medical Branch at Galveston researchers have achieved promising results with a potential new weapon against respiratory syncytial virus, the most common cause of infant hospitalization in the United States.

In an effort to find an effective antiviral therapy for RSV, the scientists tested two types of complex, custom-designed molecule to interfere with the genetic machinery that RSV uses to replicate, or copy itself, within cells. Both of the so-called morpholino oligomers, created by Oregon-based AVI BioPharma, penetrated cultured human airway cells easily and produced only minimal toxicity. One of the two, designated AUG-2, significantly reduced RSV replication in both cell culture and mouse experiments.

Viral replication is one of the major pathogenetic processes of RSV, and we badly need a specific antiviral therapy, said UTMB Dr. Roberto Garofalo, senior author of a paper on the study to be published in the June issue of Molecular Therapy and now available in the Advance Online Publication section of the journals website. That's what an agent like this morpholino could give us.

RSV infects almost all children by age two, but normally causes only a cold-like upper respiratory infection. In some babies, however, it spreads to the lungs, where the inflammation it generates causes coughing, wheezing and extreme difficulty in breathing, a life-threatening clinical syndrome known as bronchiolitis.

Recent research by Garofalo and other investigators suggests that two key factors drive RSV bronchiolitis: an inflammatory overreaction by the cells that line the airways of the lungs, and a failure to respond to RSV by T lymphocytes (also known as T cells), immune system cells that ordinarily act to control viral infections.

Because a dangerous inflammatory response occurs so soon after RSV begins replicating in the lungs, Garofalo said, antiviral therapy by itself is unlikely to be suf
'/>"/>

Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
2. China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent
3. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
4. Peter Burg Appointed as Co-Chair of the Plaintiffs Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation
5. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
6. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
7. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
8. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
9. IUPUI scientists report first 3-D view of anti-cancer agent
10. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
11. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... The ... Boston, when Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders ... the challenge. MLB is donating $100,000 to further collaborative efforts among the ALS organizations ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export Programs:, ... http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports costs time, money and ... containment — or even destruction — of products, an FDA insider shows manufacturers ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby ... post that encourages the understanding and treatment of ankle sprains. A common sports ... remedies. This can be dangerous if the condition augments and causes more disruption. ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark ... for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The ... post-acute care providers understand the benefits of using medication management technologies . ...
Breaking Medicine News(10 mins):Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... The following is a,statement by Bonnie J. Campbell, ... jury unanimously concluded that former manufacturers,of lead pigment used ... the,harm claimed by this plaintiff. The jury unanimously found ... paint., "Under Wisconsin law, property owners are legally ...
... Rhythm Congress 2007 ... Live EP Cases in Birmingham, UK, CARLSBAD, ... company, announced today its successful first,public broadcast of a procedure ... by Dr. Lucas Boersma of the St. Antonius,Hospital in Nieuwegein, ...
... five treated babies doesn,t have excess stomach acid, study ... may be overprescribing anti-reflux medications to infants, new research ... in five babies given anti-reflux medications, which work by ... levels. That means four out of five infants included ...
... of choice to manage abnormal heart rhythms, a new ... School of Medicine suggests that women with ICDs fare ... retrospective analysis to be presented at the AHA Scientific ... p.m.), lead researcher Andrea Russo, M.D., Clinical Associate Professor ...
... Guatemala, Nov. 5 World-renowned heart,surgeon Dr. Rafael Espada ... President of Guatemala. President-elect Alvaro Colom, with Dr.,Espada as ... than 52.8 percent of the country,s votes. The two ... Guatemala, Dr. Espada has practiced for more than 30 ...
... Nov. 5 Lincoln Financial,Advisors, part of ... announced today that it has entered into ... to provide its members access to,services provided ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050830/LFLOGO ) ...
Cached Medicine News:Health News:First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time 2Health News:First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time 3Health News:Anti-Reflux Drugs May Be Overprescribed in Infants 2Health News:Anti-Reflux Drugs May Be Overprescribed in Infants 3Health News:Do women fare worse with some heart devices? 2Health News:Houston Heart Surgeon Elected Vice President of Guatemala 2Health News:Lincoln Financial Advisors to Provide Exclusive Services to American Osteopathic Association Members 2Health News:Lincoln Financial Advisors to Provide Exclusive Services to American Osteopathic Association Members 3
(Date:7/30/2015)... July 30, 2015  Today we bring you a special edition of #MedicareMonday on ... you about some of our Medicare resources and continue highlighting the success of the ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the second quarter ending June 30, 2015. ... across the organization.  We are excited to be near ... trial ever conducted with topline results expected in the ... Officer, PTC Therapeutics, Inc. "Translarna is now commercially available ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... HOUSTON, May 2, 2011 Otto Kaiser Memorial Hospital ... in favor of ChartAccess® Comprehensive EHR from Prognosis Health ... 25-bed hospital comply with the federal government,s meaningful use ... health information organization (RHIO). "We,re known ...
... N.Y., May 2, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... America Merrill Lynch 2011 Health Care Conference on Tuesday, May ... Time).  The session may be accessed through the Company,s web ... archived version of the presentation will be available after the ...
Cached Medicine Technology:Otto Kaiser Memorial Hospital Turns to Prognosis ChartAccess® Comprehensive EHR to Meet Organizational Aspirations 2Otto Kaiser Memorial Hospital Turns to Prognosis ChartAccess® Comprehensive EHR to Meet Organizational Aspirations 3
... OraQuick is an FDA ... venipuncture whole blood test used ... of HIV-1 infection. This CLIA ... presence of antibodies to HIV-1, ...
... Mononucleosis test is designed to detect ... plasma or whole blood. The QuickVue+ ... of bovine erythrocytes which give a ... extracts prepared from sheep and horse ...
... available point-of-care diagnostic test that can reliably ... A and B. The test uses a ... that assists viral replication by promoting the ... The ZstatFlu substrate is labeled with a ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
Medicine Products: